dabrafenib,pdr001,nivolumab,relatlimab,trametinib
novartis,bms
['biomarker', '047 ,(-nct047),(-0.047%),(-2047)', 'combi-i', 'relativity,047']
#icymi: (of ) et al reported the exploratory biomarker analyses from the phase 3 trial of combi-i in #jitc. check it out &gt; &gt; then head over to see him present 2-year results from the relativity-047 trial at #asco23. #cim23 
The official journal of @SITCancer, covering all aspects of tumor immunology and cancer immunotherapy. #JITC Interim Editor-in-Chief: James L. Gulley (@gulley1)